Does PTCY increase the risk of infections?
M Mikulska, C Bartalucci, AM Raiola, C Oltolini - Blood Reviews, 2023 - Elsevier
PTCY has been mainly used in haploidentical transplant (haploHSCT), but its use in
matched donors allowed better evaluation of infectious risk conferred separately by PTCY or …
matched donors allowed better evaluation of infectious risk conferred separately by PTCY or …
[HTML][HTML] The benefits of the post-transplant cyclophosphamide in both haploidentical and mismatched unrelated donor setting in allogeneic stem cells transplantation
J Dybko, M Sobczyk-Kruszelnicka, S Makuch… - International Journal of …, 2023 - mdpi.com
Allogeneic hematopoietic cell transplantation (alloHSCT) is a standard therapeutic approach
for acute leukemias and many other hematologic malignancies. The proper choice of …
for acute leukemias and many other hematologic malignancies. The proper choice of …
Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation
We investigated the outcomes after adult haploidentical (haplo) and matched unrelated
donor (MUD) hematopoietic cell transplantation (HCT) in a single-center study (n= 452) …
donor (MUD) hematopoietic cell transplantation (HCT) in a single-center study (n= 452) …
[HTML][HTML] Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and …
MJ Rieger, SM Stolz, AM Müller, R Schwotzer… - Bone Marrow …, 2023 - nature.com
Hematopoietic cell transplantation from haploidentical donors (haploHCT) has facilitated
treatment of AML and MDS by increasing donor availability and became more feasible since …
treatment of AML and MDS by increasing donor availability and became more feasible since …
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
J Montoro, DJ Eikema, J Tuffnell, V Potter, K Kalwak… - Blood, 2024 - ashpublications.org
Selecting the most suitable alternative donor becomes challenging in severe aplastic
anemia (SAA) when a matched sibling donor (MSD) is unavailable. We compared outcomes …
anemia (SAA) when a matched sibling donor (MSD) is unavailable. We compared outcomes …
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies
ML Fox, I García-Cadenas, V Navarro… - Bone Marrow …, 2024 - nature.com
Despite novel cellular and immunomodulatory therapies, allogeneic hematopoietic stem cell
transplantation (HSCT) remains a treatment option for lymphoid malignancies. Post …
transplantation (HSCT) remains a treatment option for lymphoid malignancies. Post …
Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease …
P Ye, M Wu, J Cao, R Pei, J Yuan, H Zhuang… - Annals of …, 2024 - Springer
Reduced-toxicity conditioning (RIC) regimens are used for allogeneic hematopoietic stem
cell transplantation in older patients. However, successful outcomes are hindered by graft …
cell transplantation in older patients. However, successful outcomes are hindered by graft …
Haploidentical versus Cord Blood transplantation in pediatric AML. A retrospective outcome analysis on behalf of the pediatric subcommittee of GETH (Grupo Español …
L Sisinni, GXA Monserrate, JMP Hurtado… - … and Cellular Therapy, 2024 - Elsevier
Haploidentical stem cell transplantation (Haplo-SCT) and cord blood transplantation (CBT)
are both effective alternative treatments in patients suffering from Acute Myeloid Leukemia …
are both effective alternative treatments in patients suffering from Acute Myeloid Leukemia …
[HTML][HTML] Haploidentical and Matched Sibling Transplantation for Acute Myeloid Leukemia: A Hospital-Based Study
JC Baena, MC Rosales, M Estacio, A Hidalgo… - Journal of …, 2023 - ncbi.nlm.nih.gov
Background Allogeneic peripheral blood stem cell transplantation (PBSCT) has been
increasing for the last years in Latin America. The objective of this study was to describe …
increasing for the last years in Latin America. The objective of this study was to describe …
Combination of reduced post‐transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft‐versus‐host disease in human …
T Terao, T Kondo, M Nakamura, H Takasuka… - …, 2024 - Wiley Online Library
We evaluated the clinical impacts of the concurrent modification of post‐transplant
cyclophosphamide (PTCy) dose and tacrolimus (Tac)‐initiation timing in 61 patients with …
cyclophosphamide (PTCy) dose and tacrolimus (Tac)‐initiation timing in 61 patients with …